EGFR and non-small cell lung carcinoma: Only one case of grade 4 myelosuppression was reported and resolved after supportive care.<h4>Conclusions</h4>High-dose Furmonertinib combined with IP is an effective and well-tolerated regimen for EGFR-mutant NSCLC-LM.